“Mark Benedyk, Ph.D., President and CEO of Telephus Medical” Pulmotect, Inc., a clinical-stage biotechnology company developing PUL-042, fast-acting pulmonary immune stimulant for the treatment of antibiotic-resistant respiratory infections, today announced that Mark Benedyk, Ph.D., President and CEO of Telephus Medical, was appointed to the Company’s board of directors. “Mark is a highly respected CEO and […]
